ZBH241220C115000
- 0.03
- -0.02-40.00%
Zimmer Biomet Holdings Newsroom
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $130
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $118
Bernstein Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $133
Zimmer Biomet Holdings Analyst Ratings
J.P. Morgan Upgrades Zimmer Biomet Holdings(ZBH.US) to Buy Rating, Raises Target Price to $128
Zimmer Biomet Holdings Analyst Ratings
Barclays Cuts Zimmer Biomet Price Target to $118 From $125, Maintains Underweight Rating
Citi Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $120
Morgan Stanley Initiates Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $115
Wells Fargo Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Hold Rating for Zimmer Biomet Holdings Amid Uncertain Impact of New Product Launch in US Market
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Zimmer Biomet Holdings Is Maintained at Outperform by RBC Capital
Zimmer Biomet Holdings Analyst Ratings
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $125
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Viridian Therapeutics (VRDN) and Select Medical (SEM)
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $117
Zimmer Biomet Holdings Analyst Ratings
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $117 to $140
Zimmer Biomet Holdings Is Maintained at Equal-Weight by Wells Fargo